SSA Listing 4.02C: Functional Capacity Without Exercise Tolerance Test

Direct answer

When a claimant with chronic heart failure cannot complete an exercise tolerance test (ETT) because of a non-cardiac condition such as severe knee osteoarthritis, Listing 4.02B3 is unavailable as a functional-capacity pathway. That paragraph requires the inability on the ETT to be "due to" specified cardiac manifestations—namely "dyspnea, fatigue, palpitations, or chest discomfort" or defined ventricular ectopy [1]. A musculoskeletal limitation breaks that causal chain. The claimant must instead satisfy the 4.02B functional criterion through an alternative paragraph: either B1 (persistent symptoms severely limiting ADLs with an MC determination that exercise testing would present a significant risk) or B2 (three or more acute CHF episodes requiring extended physician intervention within 12 months) [1]. Drug-induced stress testing is recognized elsewhere in the cardiovascular listings as a non-exercise alternative modality [2], which may be relevant to the overall evaluation, though 4.02B3's text expressly requires an "exercise tolerance test" [1].

Analysis

The "due to" requirement in 4.02B3 forecloses reliance on non-cardiac test-limitation

Listing 4.02B3 provides that the listing is met when there is:

> "Inability to perform on an exercise tolerance test at a workload equivalent to 5 METs or less due to: > a. Dyspnea, fatigue, palpitations, or chest discomfort; or > b. Three or more consecutive premature ventricular contractions (ventricular tachycardia), or increasing frequency of ventricular ectopy with at least 6 prema[ture ventricular contractions]" [1].

The operative word is "due to." The paragraph requires a causal nexus between the inability to reach the 5-MET workload and specific cardiac signs or symptoms. A claimant who stops the treadmill—or who cannot attempt it at all—because of knee pain from osteoarthritis has not demonstrated inability "due to" dyspnea, fatigue, palpitations, chest discomfort, or the specified arrhythmias. The non-cardiac impairment, not the heart failure, is the limiting factor. Accordingly, B3 cannot be satisfied on that record.

Alternative pathway: 4.02B1—MC significant-risk determination plus persistent symptoms

Listing 4.02B1 does not depend on ETT results at all. It requires:

> "Persistent symptoms of heart failure which very seriously limit the ability to independently initiate, sustain, or complete activities of daily living in an individual for whom an MC, preferably one experienced in the care of patients with cardiovascular disease, has concluded that the performance of an exercise test would present a significant risk to the individual" [1].

This paragraph has two distinct elements:

1. MC risk determination. A medical consultant—preferably one experienced in cardiovascular care—must conclude that performing an exercise test "would present a significant risk to the individual." The listing text does not expressly limit "significant risk" to cardiac risk; it speaks of risk "to the individual" broadly [1]. In practice, this determination is most commonly made when exercise testing is medically contraindicated due to the cardiac condition itself (e.g., unstable angina, severe arrhythmia, or decompensated heart failure). Whether a purely musculoskeletal inability to exercise qualifies as a "significant risk" under B1 is not directly addressed by the provided listing text. Practitioners should secure an explicit MC opinion articulating the basis for the risk determination and, where possible, tie the inability to perform the test to the overall medical presentation rather than to the knee osteoarthritis alone.

1. Persistent symptoms very seriously limiting ADLs. Independent of the MC determination, the claimant must show persistent heart-failure symptoms that "very seriously limit the ability to independently initiate, sustain, or complete activities of daily living" [1]. This is a functional standard assessed from the clinical record: treatment notes, physician observations, claimant statements regarding ADLs, and any other evidence reflecting the day-to-day impact of the heart failure.

Alternative pathway: 4.02B2—recurrent acute CHF episodes

Listing 4.02B2 is entirely independent of exercise testing. It requires:

> "[t]hree or more separate episodes of acute congestive heart failure within a consecutive 12-month period, with evidence of fluid retention from clinical and imaging assessments at the time of the episodes, requiring acute extended physician intervention such as hospitalization or emergency room treatment for 12 hours or more, separated by periods of stabilization" [1].

If the claimant's history includes the requisite number of qualifying episodes—with contemporaneous fluid-retention evidence on clinical and imaging assessment and the specified duration of acute intervention—this paragraph satisfies the 4.02B functional criterion without any need for an ETT.

Drug-induced stress testing as an alternative modality

Listing 4.04C, addressing ischemic heart disease, references "a timely normal drug-induced stress test" as part of the evaluation framework, specifically in the context of cases where an MC has concluded that exercise tolerance testing "would present a significant risk to the individual" [2]. The full provision states:

> "in the absence of a timely exercise tolerance test or a timely normal drug-induced stress test, an MC, preferably one experienced in the care of patients with cardiovascular disease, has concluded that performance of exercise tolerance testing would present a significant risk to the individual" [2].

This demonstrates that the cardiovascular listings recognize pharmacological (drug-induced) stress testing as an alternative to treadmill exercise. For a claimant who cannot undergo treadmill testing due to knee osteoarthritis, a drug-induced stress test (e.g., dobutamine or vasodilator stress with imaging) may be clinically appropriate because it does not require locomotor capacity. However, the text of 4.02B3 specifically requires an "exercise tolerance test" and lists cardiac symptoms as the reason for inability [1]; it does not expressly provide for substitution of a drug-induced stress test. The more directly applicable alternative under 4.02 is the B1 pathway, which dispenses with exercise testing altogether upon the MC's risk determination [1].

Sequential evaluation if no 4.02B paragraph is met

If the claimant meets 4.02A (documented systolic or diastolic failure) but cannot satisfy any paragraph of 4.02B—because the ETT is precluded by non-cardiac factors, B1's MC risk determination is not secured, and B2's hospitalization threshold is not met—the listing is not met. Evaluation proceeds to residual functional capacity (RFC) assessment and the grid framework. The grid rules analyze the combination of vocational factors (age, education, work experience) with RFC, expressed as maximum sustained work capability at sedentary, light, medium, heavy, or very heavy exertional levels [10]. The claimant's cardiovascular limitation—assessed from all available evidence short of a completed ETT—would be incorporated into the RFC, along with any musculoskeletal limitations from the knee osteoarthritis.

Key points

• 4.02B3's "due to" clause is disqualifying. The inability to perform on the ETT must be "due to" dyspnea, fatigue, palpitations, chest discomfort, or specified ventricular ectopy [1]. Knee osteoarthritis is a non-cardiac factor and does not satisfy this causal requirement.

• 4.02B1 is the primary alternative. It requires (a) persistent heart-failure symptoms that "very seriously limit" ADLs and (b) an MC determination that exercise testing "would present a significant risk to the individual" [1]. No ETT is required under this paragraph. Secure an explicit, well-reasoned MC opinion on the risk determination.

• 4.02B2 is fully independent of exercise testing. Three or more qualifying acute CHF episodes with fluid-retention evidence, each requiring 12+ hours of acute extended physician intervention within a consecutive 12-month period, satisfies the functional criterion [1].

• Drug-induced stress testing is recognized in the cardiovascular listings. Listing 4.04C references a "drug-induced stress test" as a recognized testing modality [2]. While not expressly substituted for the ETT in 4.02B3, pharmacological stress imaging may provide relevant cardiac functional data for the RFC assessment and may support the medical picture underlying a B1 determination.

• If no B paragraph is met, proceed to RFC and grids. The grid framework evaluates RFC (maximum sustained work capability) in combination with age, education, and past work [10]. Both the cardiac and musculoskeletal limitations should be reflected in the RFC.